Want to see AU:RHY full AI Analyst Report?
RHY Stock Chart & Stats
AU$0.10
-AU$0.01(-11.11%)
At close: 4:00 PM EDT
AU$0.10
-AU$0.01(-11.11%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.28
Previous CloseN/A
Volume360.17K
Average Volume (3M)225.55K
Market Cap
AU$29.12M
Enterprise ValueAU$28.21
Total Cash (Recent Filing)AU$3.44M
Total Debt (Recent Filing)AU$247.98K
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding364,059,840
10 Day Avg. Volume169,887
30 Day Avg. Volume225,549
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)8.36
Price to Sales (P/S)356.41
P/FCF Ratio-5.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageLow debt and positive equity provide some financial flexibility while the company develops its diagnostic products. This reduces immediate balance-sheet pressure and may leave more capacity for operating investment, although continued losses could still erode the capital base over time.
Demonstrated Revenue PotentialThe strong FY2025 revenue increase shows that the business has previously generated materially higher sales than its latest result. If commercial execution improves, that demonstrated revenue capacity could support recovery, though the historical volatility means it has not yet become a reliable trend.
Focused Diagnostic StrategyA focused IVD strategy centered on colorectal cancer screening gives the company a defined product direction and target clinical application. Concentrating development around ColoSTAT may help align resources and commercial efforts, provided the product progresses successfully toward broader adoption.
Bears Say
Persistent UnprofitabilityPersistent losses indicate that the current business has not yet achieved sustainable operating profitability. Continued negative earnings can constrain reinvestment, weaken the capital base, and increase dependence on future funding until revenue scale and cost absorption improve materially.
High Cash BurnSustained negative operating and free cash flow means the company is consuming cash rather than funding operations internally. This can limit development flexibility and create ongoing reliance on cash reserves or external funding, making financial sustainability dependent on reversing the burn rate.
Unstable Revenue BaseThe sharp revenue decline and negative gross profit show that commercial activity remains too inconsistent to support a stable cost structure. Such volatility makes forecasting difficult, weakens operating leverage, and increases the risk that future development spending will not be covered by recurring sales.
Rhythm Biosciences Ltd. News
RHY FAQ
What was Rhythm Biosciences Ltd.’s price range in the past 12 months?
Rhythm Biosciences Ltd. lowest share price was AU$0.07 and its highest was AU$0.28 in the past 12 months.
What is Rhythm Biosciences Ltd.’s market cap?
Rhythm Biosciences Ltd.’s market cap is AU$29.12M.
When is Rhythm Biosciences Ltd.’s upcoming earnings report date?
Rhythm Biosciences Ltd.’s upcoming earnings report date is Feb 24, 2027 which is in 159 days.
How were Rhythm Biosciences Ltd.’s earnings last quarter?
Rhythm Biosciences Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.011 earnings per share for the quarter.
Is Rhythm Biosciences Ltd. overvalued?
According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued.
Does Rhythm Biosciences Ltd. pay dividends?
Rhythm Biosciences Ltd. does not currently pay dividends.
What is Rhythm Biosciences Ltd.’s EPS estimate?
Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rhythm Biosciences Ltd. have?
Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.
What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?
Rhythm Biosciences Ltd. reported an EPS of -AU$0.011 in its last earnings report. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?
Currently, no hedge funds are holding shares in AU:RHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Biosciences Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
68.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rhythm Biosciences Ltd.
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―
Microba Life Sciences Limited
―